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1. Introduction
Japanese encephalitis (JE) is among the most significant viral encephalitis in Asia, particularly
in rural and suburban areas where rice culture and pig farming coexist. It has also occurred
rarely and occasionally in northern Australia and some parts of the western pacific. JE is caused
due to infection with the JE virus (JEV), a mosquito borne flavivrus. The main JEV transmission
cycle involves Culex tritaeniorhynchus mosquitoes and similar species that lay eggs in rice
paddies and other open water resources, with pigs and aquatic birds as principal vertebrate
amplifying hosts [Han et al., 2012]. Humans are generally considered as dead-end JEV hosts
i.e. they rarely develop enough viremia to infect feeding mosquitoes. Nearly 20-30% of JE cases
are fatal and 30-50% of survivors have major neurological disorders [Bhattacharyya et al.,
2013]. JE is mostly a disease of children but other age groups may be affected [Kundu et al.,
2013; Griffiths et al., 2013; Larena et al., 2013]. In most temperate areas of Asia, JEV is transmitted
mainly during summer season, when large epidemics can occur. In the tropics and subtropics
region, transmission can occur throughout the year but often increases during the rainy season
[Campbell et al., 2011]. The first epidemic of JE was recorded in Japan in 1871. Major outbursts
have been seen in nearly every 10 years. In 1924 more than 6,000 cases were reported in a major
outbreak in Japan [Solomon et al., 2000]. The disorders caused by JEV began from Southeast
Asia and now it’s affecting people worldwide [Liu et al., 2013; Li et al., 2013]. Nearly 30 million
people are at danger of JEV infection [Saxena et al., 2003]. Though intensive care and support
are able to lower the death rate but patients continue to suffer from this disease for a long
period of time. Some effects such as learning difficulties and behavioral problems can remain
masked for several years.
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2. Epidemiological features
JE is believed to be originated in Indonesia and Malaysia long back in mid 1500s [Weaver et
al., 1999; Sinniah et al., 1989]. JEV leads to major outbreaks in both temperate regions of Asia
like China, Japan, Korea, Philippines, Taiwan and tropical regions like Bangladesh, India, Sri
Lanka and Nepal [Bista et al., 2005]. The cases of JE are also reported in newer geographical
regions in the Torres Strait islands of Australia and in Papua New Guinea [Fig. 1]. The reason
for this wide spread of JE is unknown but it may be due to population shift or variations in
agricultural practices, animal husbandry, climate, ecology or migratory birds patterns. In India
the first case of JE was seen in 1955. JE is reported to be endemic in many parts such as Assam,
Bihar, Madhya Pradesh, Tamil Nadu, Uttar Pradesh and West Bengal.
Figure 1. Epidemiology of JE globally. The areas highlighted in red display the endemic regions affected by JE.
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3. Viral replication and morphogenesis
JEV virion comprises of a single strand of positive-sense RNA of around 11kb, enclosed in a
nucleocapsid and surrounded by envelope made up of glycoproteins [Agrawal et al., 2013; Ye
et al., 2012]. The RNA consists of a short 5’ untranslated region (UTR), a longer 3’ UTR and a
single open reading frame between them. It encodes 3432 aminoacid polyprotein, which is
translationally and post translationally cleaved by viral and host proteases into three structural
proteins (core-C, pre-membrane-PrM and envelope-E) and seven nonstructural (NS) proteins
(NS1,NS2A,NS2B,NS3,NS4A,NS4B and NS5) [Fig 2][Yang et al., 2013].
Figure 2. Organization of the JEV genome
The C protein of 12-14 kDa in size is highly basic and fuses with the RNA to form the nucleo‐
capsid. The PrM is in close proximity with the E protein, forming a heterodimer and is believed
to act as a ‘chaperone’ to it, hindering its function until after virion release. Just before the
virion release, the PrM protein is cleaved by a protease to its mature M protein form. This
alteration contributes for the formation and activation of E protein homodimers. Researchers
suggested that the extremely conserved N glycosylation motif N15-X16-T17 in JEV PrM and its
N-glycan substituents are essential for several stages of JEV biology: PrM biogenesis, virus
release and pathogenesis. The E protein is the largest structural protein, comprising of
approximately 500 aminoacids, with up to two potential glycosylation sites. It is the main target
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for the humoral immune response and is believed to play a vital role in viral entry into host
cells [Solomon et al., 2003]. The xlink protein is involved in virus replication and regulation of
the innate immune response [Li et al., 2012; Zhang et al., 2012]. The functions of NS3 and NS4
are prominent, they code for serine protease and RNA dependent RNA polymerase (RdRp)
[Lu et al., 2013]. There is a high rate of mutation in JEV because RdRp is expected to have some
error which leads to vast alterations in genomic sequences of JEV worldwide [Saxena et al.,
2008]. Since all flaviviral NS proteins are essential for viral replication, any one of them can be
selected as target for selective inhibitors of viral replication for therapeutic intervention
[Anantpadma et al., 2011; Mastrangelo et al., 2012].
4. Pathogenesis
The development of JEV infection, beginning from its entry till reaching its site of action, the
central nervous system (CNS) is not well understood. Studies with other flaviviruses have
brought us to the belief that upon entry through mosquito bite, the virus infects dendritic cells
in the skin and is carried to the nearest draining lymph nodes, thereby initiating a round of
early immune response. But this response is not enough to counter the virus. Meanwhile the
virus spreads to secondary lymphoid organs before entering the blood circulation through the
efferent lymphatic system. During the subsequent transient viremia, peripheral organs such
as kidney, liver and spleen are known to be infected first, after which the neurotropic virus
spreads to the CNS. It is still not clear how JEV is able to escape the host’s peripheral immune
response. After the virus escapes the immune system, it crosses the Blood Brain Barrier to enter
the CNS. JEV may cross the BBB by passive transport across the endothelium, by active
replication in endothelial cells or by a ‘Trojan Horse’ mechanism in which the virus is carried
into the brain by infected inflammatory cells. Monocytes and macrophages are considered to
be the feasible carriers of the virus in the CNS as the virus can survive for a prolonged time
and effectively replicate within these cells. During the entry of infected monocytes and
macrophages through the BBB, change in the structural and functional integrity of the BBB,
leads to production of matrix metalloproteases released by endothelial cells of BBB. This
further result in deterioration of BBB stability. BBB stability. Due to the compromised func‐
tioning of the BBB, peripheral inflammatory cells are recruited to the infected brain that extends
the neuronal impairment.
JEV causes neuronal damage in the brain. However in several cases, JEV is possibly not directly
involved in the destruction of brain tissue but it may activate microglia and trigger cell-
mediated immune response. Microglial cells are the resident immune cells of the CNS and
have a crucial role in host defense against invading microorganisms. Microglial activation is
considered as an adaptive response whereby microglia release neuroprotective factors to ease
the recovery of injured neurons. They also perform phagocytosis for dying or damaged
neurons, before they lyse and release toxic agents into surrounding areas. JEV infection
activates microglia both morphologically and functionally, in vivo, which causes rise in the
level of pro-inflammatory mediators, such as IL-6, TNF-α, RANTES and MCP-1 [Thongtan et
al., 2012]. These proinflammatory mediators and cytotoxins released from activated microglia
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are involved in inducing neuronal death that complements JE. Neuronal death by secreted
TNF is mediated by the TNF receptor-associated death domain protein (TRADD), which there
upon regulates a downstream apoptotic cascade, in neurons [Swarup et al., 2007]. During JEV
infection, nitric oxide (NO) is released by macrophages and plays a significant role in inflam‐
mation, even though NO itself is a strong antimicrobial agent, researchers have suggested that
it strongly inhibits synthesis of viral RNA, protein accumulation and virus release from
infected cells. NO production is higher in the JEV infected brain, and plays a crucial role in the
innate immunity of the host and its ability to restrict the initial stages of JEV infection in the
CNS [Saxena et al., 2000].
In addition to neuronal and microglial cells, astrocytes are also infected by JEV. Astrocytes are
known to maintain homeostasis in the CNS and support the survival and information
processing function of neurons. They respond fast to CNS infection and help regulate neuro‐
inflammation. JEV infection results in astrocyte activation, but the infection overpowers the
capacity of activated astrocytes to maintain metabolic homeostasis, resulting in an over
accumulation of toxic byproducts of metabolism that are injurious to neuronal viability.
However JEV infection triggers metabolic reprogramming by upregulating the expression of
many proteins such as IP-10, ceruloplasmin and glutamine synthase by astrocytes, involved
in the metabolic pathways vital for maintaining neuronal health. This increase is deficient to
meet the increased demand that accompanies JEV infection. Astrocytes help in the transmis‐
sion of JEV from peripheral tissues to the cerebrospinal fluid.
Disease course Incubation period Signs and symptoms
Prodromal stage 1-6 days Fever, muscle pain, headache along with vomiting. In children
gastrointestinal symptoms like nausea, vomiting, diarrhea and
abdominal pain may be prominent.
Acute encephalitic
stage
7-13 days Photophobia, hyperexcitability, focal and neurological signs,
muscular rigidity, dull, mask like face with wide unblinking eyes,
tremor, widespread hyertonia, cogwheel rigidity, other
irregularities in movement, upper motor neuron signs, cerebellar
signs and cranial nerve paralysis sometimes leading to coma
Late convalescent
stage
14-15 day onwards Fever subsides, neurological signs may improve, and eventually
either death may occur, or a long term psychoneurological
condition may persist, if patient survives.
Table 1. Duration, signs and symptoms of Japanese encephalitis
JE usually develops in patients after an incubation period of 5-15 days [Table 1]. In humans,
most JEV infections are asymptomatic, with about 1 in 300 JEV infections resulting in symp‐
toms ranging from non-specific mild fever to severe meningoencephalitis categorized by fever,
lessened consciousness, seizures and focal neurological signs. At later stages, poliomyelitis-
like flaccid paralysis and parkinsonian syndrome develop, which exhibit the standard
description of JE like dull, flat and mask-like face with wide, unblinking eyes, tremor, wide‐
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spread hypertonia, cogwheel rigidity and other irregularities in movement [Dutta et al., 2010].
Paralysis of the upper body is more common than that of legs. Nearly 30% of survivors have
genuine persistent motor deficits and approximately 20% have severe cognitive and language
impairment [Mackenzie et al., 2004].
5. Transmission
The JE virus exists in a zoonotic transmission cycle between mosquitoes and pigs and/or water
birds; humans get infected only accidentally when bitten by an infected mosquito [Fig 3] and
are a dead-end host [Gould et al., 2008]. JEV has been isolated from many mosquito species in
field studies, and even though the major mosquito vectors differ in diverse geographical
regions, the most important is Culex tritaeniorhynchus. For Eastern Asia, Southern Asia and
Southeastern Asia, the chief vector is C. tritaeniorhynchus [Rao et al., 2001]. For Northern
Australia, the chief vector is C. annulirostris. From India’s outlook, there are several other
secondary vectors such as Anopheles peditaeniatus, A. subpictus, C. epidesmus, C. gelidus, C.
pseudovishnui, C. whitemorei, Mansonia uniform and M. Indiana [Borah et al., 2013]. Pigs are the
key component in the transmission cycle with respect to human infection, while egrets, herons
and other ardeid birds are significant maintenance hosts [Hecker et al., 2013; Sarkar et al.,
2013]. Of other vertebrates, horses can develop CNS infection but are a dead-end host; Other
domestic animals may also get infected, but do not show any evidence of viremia. Rodents are
refractory to infection; and amphibians, bats and reptiles can be infected experimentally and
virus can persist, but the role of these species in hibernating and maintaining the virus in the
environment is undisclosed.
There are two epidemiological forms of transmission: an endemic form in tropical areas with
virus circulation almost throughout the year, but with a wide seasonal peak probably due to
irrigation practices; and an epidemic form in more temperate areas with clear summer
seasonality [Schuh et al., 2013; Gao et al., 2013]. Subsequently, JE is mainly a rural disease, where
Cx. tritaeniorhynchus mosquitoes breed in rice paddies and pigs provide the main source of
blood meals, with the consequence of transmission cycles in close proximity to human
habitation.
6. Diagnosis
Patients with JE present many signs of acute encephalitic syndrome. There are various possible
causes of acute encephalitic syndrome; therefore laboratory confirmation is crucial for the
accurate diagnosis of JE [Table 2], which is a tough task because of very low viremia. Reverse
passive hemagglutination, immunofluorescence and staphylococcal coagglutination tests
using polyclonal or monoclonal antibodies have proved the value of antigen detection in
Cerebrospinal fluid (CSF) for rapid diagnosis of JE. Advanced methods like Immunogold silver
staining (IGSS), have been effectually used in the detection of antigen in mononuclear cells of
peripheral blood and CSF of patients. Immunohistochemistry has been used to detect viral
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antigens in the CNS. Histopathology inspection is also very obliging for clinical association
and diagnosis of JEV. Diagnosis is accordingly targeted towards the detection of antibodies in
serum and cerebrospinal fluid. Cases like cross-reactivity of antibodies to other flaviviruses
cause confusion in the diagnosis of JEV. IgM capture ELISA has been the most extensively
used diagnostic method for JE detection [Hobson-Peters et al., 2012; Palani et al., 2013;
Borthakur et al., 2013]. Currently, dipstick method, JEV-CheX and reverse transcriptase PCR
are some of the methods which are used for the early detection of JEV [Yang et al., 2013; Seo
et al., 2013; Zheng et al., 2013].
Diagnostic tool Detects
Immunogold Silver Staining (IGSS) Antigens in mononuclear cells peripheral blood and CSF
Hemagglutination test Antigens in CSF
MAC-ELISA IgM antibodies
Dipstick method, JEVCheX Antibodies
RT-PCR, RT-LAMP Universal oligonucleotide primers
Table 2. Laboratory diagnostic tools for Japanese encephalitis
Figure 3. Transmission cycle of Japanese encephalitis virus. Infected Culex mosquitoes (vectors) play the role in the
spread of JEV. Pigs are the amplifying hosts and birds (egrets) are the maintenance hosts while humans are the dead-
end hosts.
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7. Treatment
Currently there is no therapy for JE [Saxena et al., 2009]. Presently, chemotherapy during JE is
mainly supportive and not targeted towards JEV specifically. Interferon therapy has not
proved to be a great success [Tiwari et al., 2012]. Naturally occurring compounds such as
arctigenin, a phenylpropanoid and rosmarinic acid, which is a phenolic compound found in
many Labiatae provide protection to mice against JEV GP78 by noticeably decreasing JEV
induced neuronal apoptosis, activation of microglial cells, active caspase activity and induction
of proinflammatory mediators in the brains of the infected animals.
An in vivo study has shown that minocycline reduces neuronal apoptosis, activation of
microglial cells, active caspase activity, proinflammatory mediators and viral titer on later
stages after infection. Another compound, N-methylisatin-β-thiosemicarbazone derivative is
known to inhibit JEV replication completely in vitro. Glucosidase inhibitors of the endoplasmic
reticulum such as N-nonyl-deoxynojirimycin, which block the trimming step of N-linked
glycosylation, have been shown to eliminate the production of many endoplasmic reticulum-
budding viruses, including dengue type-II and JEV. Another recent study carried out in mice
using RNA interference showed that a single intracranial organization of lentiviruses deliv‐
ering short hairpin RNA or lipid-complexed small interfering RNA (siRNA) either before or
after the viral challenge was sufficient to provide protection against lethal encephalitis. From
the study it was clear that by precise drug design of the conserved site, a single siRNA
treatment could suppress viral infection across species, thus enhancing the treatment of acute
viral infections with overlapping clinical symptoms [Ghosh et al., 2009].
8. Protection
The control of JE is based mainly on three measures: mosquito control, avoiding human
exposure and immunization. Mosquito control has failed to be an effective measure and suffers
from the lack of research into new pesticides. Avoiding complete exposure from infected
mosquitoes is not practically possible. Accordingly, immunization is the only effective method
for long-term protection. To prevent JE, it is crucial to apply a large scale vaccination for the
human population in JE prone areas [Tiwari et al., 2012]. There are many groups of vaccines
[Table 3] which are presently in use such as purified, formalin-inactivated mouse brain derived
and cell culture derived live attenuated vaccine [Lin et al., 2013]. Several vaccines are still in
different stages of development such as DNA vaccines, recombinant virus based/chimeric
vaccines [Li et al., 2013]. In most countries, the currently available vaccine for use is an
inactivated vaccine derived from mouse brain, which is manufactured in many regional
countries, but it is costly, involves three doses, needs boosting at quite frequent intervals, may
be less effective due to antigenic variation and gives rise to a number of vaccine related adverse
reactions [Yun et al., 2013].
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Vaccine Source Characteristics
(i) Formalin-inactivated mouse brain
derived Nakayama strain
Costly, less effective and side effects are
seen
(ii) Inactivated hamster kidney cell
vaccine Beijing strain Very less side effects are seen
(iii) Live attenuated hamster kidney
cell line vaccine SA14-14-2 strain, China
Costly but effective and very less side
effects are seen
Table 3. Comparison of vaccine for Japanese encephalitis
There are several side effects of JE vaccination. Side effects which are mainly seen after
vaccination are redness, swelling and tenderness. Rarely systematic adverse reactions are also
seen after vaccination like headache, myalgia, abdominal pain and skin rash. Some recipients
of the vaccine had very rare major neurological side effects [Sohn et al., 2000]. To avoid some
of the adverse reactions, vero cell grown inactivated vaccines are being examined and some
of them are currently in clinical trials. Live attenuated vaccines seem to offer good hope; some
of the advantages are that these provide long lasting immunity and are very sensitive.
Currently, the only potential vaccine is the Chinese SA 14-14-2 strain [Verma et al., 2012].
Protein-protein interaction is essential for various cellular functions and impeding such
interactions using synthetic composites is a very noteworthy idea for formulation of new
pharmaceuticals [Haridas et al., 2013].
9. Conclusion
JE is a neurological disease caused by a mosquito-borne JEV. Unlike smallpox and polio, JEV
cannot be completely eradicated because of its enzootic nature of transmission. Ever since its
discovery, JEV has continued to expand its activity into new regions, while many JE vaccines
have been made commercially available in different parts of the world. Concern about its
spread has been emphasized by the recent emergence and spread of JEV in northern Australia,
making it a major concern for global public health. Currently, prevention of infection with
most arboviruses relies primarily on efforts to control vector populations by spraying repel‐
lents, wearing protective clothing and reducing breeding places.
One of the most important research areas is the development of an ideal JE vaccine: one that
is nontoxic, less expensive and more effective and that provides life-long protection with a
single dose. The development of such a vaccine will be greatly aided by a expanding our
knowledge of JEV replication and pathogenesis at the molecular level, which has now become
technically possible with the use of infectious JEV SA14-14-2 cDNA technology. This technol‐
ogy also has huge potential for developing JEV SA14-14-2 as a vaccine vector to deliver foreign
gene(s), as has already been accomplished with infectious YFV 17D cDNA technology.
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